Paradigm Biopharmaceuticals Limited (ASX:PAR)
Paradigm Biopharmaceuticals Limited (ASX:PAR) is a late-stage drug development company with the mission to develop and commercialise Pentosan Polysulfate Sodium (PPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, ageing, degenerative disease, infection or genetic predisposition.
Paradigm's approach to market is driven by core competencies and experience at both board and executive level in clinical and commercial pharmaceutical development. Over 30% of new drugs approved or launched globally represent older drugs repurposed for new indications, reformulations or new combinations of existing drugs.
The Company's approach is to take an existing approved drug that has demonstrated safety in its approved indication/s and then repurposing that drug for a new, patented therapeutic application.
By following this approach, Paradigm is able to achieve a reduction in the time, cost and risk associated with the clinical and commercial development pathway to taking new products to market.
Paradigm Biopharma's primary focus to date is its pipeline indications covering the use of PPS, supported by full patent and IP protection. The Company's immediate commercial focus is the repurposing of PPS for the treatment of Osteoarthritis.